Study for prevention of novel coronavirus pneumonia (COVID-19) in high risk population by Chinese medicine

Study on the prevention of COVID-19 with Chinese medicine regulating constitution

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000031955

Enrollment

Unknown

Registered

2020-04-16

Start date

2020-04-01

Completion date

Unknown

Last updated

2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

control group:General basic epidemic prevention measures

sachet group:General basic epidemic prevention measures + Traditional Chinese medicine sachet

Oral and nasal spray group:General basic epidemic prevention measures + Oral and nasal spray

Oral Chinese medicine group:General basic epidemic prevention measures + Traditional Chinese medicine for epidemic prevention in high risk groups

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) novel coronavirus pneumonia has not been stopped since the outbreak of COVID-19; (2) the co worked personnel were diagnosed as COVID-19 or asymptomatic infection or SARS-CoV-2 IgM positive within 14 days; (3) the detection of nucleic acid, IgM and IgG of SARS-CoV-2 was negative within 1 weeks; (4) between 18-70 years old; (5) voluntarily accepted clinical observation and signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients diagnosed with COVID-19; (2) positive nucleic acid test; (3) positive IgM of SARS-CoV-2; (4) positive IgG of SARS-CoV-2; (5) pregnant or preparing pregnant women, lactating women, men preparing for pregnancy; (6) major diseases such as malignant tumor, end-stage renal disease, serious Alzheimer's disease; (7) those who have participated in or are participating in other clinical trials within one month; (8) Mental disorders can not express their own feelings; (9) there are other circumstances that are not suitable for inclusion in the study.

Design outcomes

Primary

Measure	Time frame
SARS-CoV-2;SARS-CoV-2 IgM Antibody;SARS-CoV-2 IgG Antibody ;	—

Secondary

Measure	Time frame
Covid-19 symptoms;TCM Constitution;Total IgG;Total IgA;IFN-a;IFN-ß;Anxiety Index;Anti inflammatory experiment in vitro;	—

Countries

The People's Republic of China

Contacts

Public ContactLingru Li

Beijing University of traditional Chinese Medicine

Lilingru912@163.com+86 13426096071

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 14, 2026